within Pharmacolibrary.Drugs.ATC.V;

model V04CA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 100 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tolbutamide is a first-generation sulfonylurea oral hypoglycemic agent, once widely used for the treatment of type 2 diabetes mellitus. It acts by stimulating insulin release from pancreatic beta cells. Although tolbutamide has largely been replaced by second-generation sulfonylureas and other agents, it may still be seen in certain contexts or older studies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Choi, MR, et al., &amp; Kang, HE (2014). Pharmacokinetics of tolbutamide and its metabolite 4-hydroxy tolbutamide in poloxamer 407-induced hyperlipidemic rats. <i>Biopharmaceutics &amp; drug disposition</i> 35(5) 264–274. DOI:<a href=&quot;https://doi.org/10.1002/bdd.1893&quot;>10.1002/bdd.1893</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24590592/&quot;>https://pubmed.ncbi.nlm.nih.gov/24590592</a></p></li><li><p>Choi, JS, &amp; Shin, SC (2003). Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. <i>Archives of pharmacal research</i> 26(11) 979–983. DOI:<a href=&quot;https://doi.org/10.1007/BF02980209&quot;>10.1007/BF02980209</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14661866/&quot;>https://pubmed.ncbi.nlm.nih.gov/14661866</a></p></li><li><p>Bae, HY, et al., &amp; Choi, JS (2002). Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. <i>Research communications in molecular pathology and pharmacology</i> 111(5-6) 237–244. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15244039/&quot;>https://pubmed.ncbi.nlm.nih.gov/15244039</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V04CA01;
